Guardant360® is a next-generation sequencing (NGS) liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from blood samples. The test provides guideline-recommended genomic results to oncologists in just 7 days from sample receipt at the laboratory, for timely assigning targeted therapy to patients with advanced solid tumors.
Guardant360® detects somatic variants in a targeted panel of 74 genes and high microsatellite instability (MSI-High). The test is approved by FDA as a companion diagnostic for non-small cell lung cancer (NSCLC) treatments – TAGRISSO® (osimertinib), RYBREVANTTM(amivantamabvmjw), and LUMAKRASTM(sotorasib).
With liquid biopsies, you can avoid the complications and delays of invasive tissue biopsies. The quick turnaround time of liquid biopsy test results which is approximately seven days upon sample receipt in the laboratory makes quick and accurate treatment decisions a reality. Comprehensive liquid biopsies are a feasible alternative to pick up actionable tumor mutations missed during tissue biopsies.
Guardant360 covers alterations in over 70 genes relevant to multiple solid tumors including MSI-High.
Remark: When no biomarker is identified with Guardant360®, Guardant360 TissueNextTM is an alternative assessment when initially requested by the ordering provider.
Guardant Health precision oncology products – Guardant
RevealTM, Guardant360® CDx, Guardant360 TissueNextTM
are available in Hong Kong through the designated local partner, Codex
Genetics.
The retrieved liquid or tumor biopsy will be performed at Guardant
Health laboratory in California, the United States.
Patients are encouraged to discuss genetic testing options with their
healthcare provider. For questions about how to access the tests, please
feel free to
contact us.
Sample shipment will be arranged on the same or the next day upon sample
retrieval. Upon sample received in Guardant Health laboratory in the US,
the test report will be ready in around 7 days.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.
Codex Genetics enables precision medicine through AI-powered analytics on both genetic and clinical data. We aim to provide holistic, clinically actionable disease management solutions for medical professionals and individuals. We provide services to accelerate diagnostic processes and help disease treatment and disease management.
